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The aim of this study was to examine whether the
immune modulator resiquimod, which belongs like
imiquimod to the imidazoquinolines, is capable of
in£uencing IgE synthesis. Peripheral blood mono-
nuclear cells from normal donors and patients with
atopic dermatitis and with seasonal allergic rhinitis
were analyzed in the presence of resiquimod, anti-
CD40þ interleukin-4 stimulation for induction of IgE,
and anti-CD40þ interleukin-4 in the presence of resi-
quimod, respectively. Our data show that spontaneous
IgE production was inhibited in the presence of resiqui-
mod, which was strongest at 10 ng per ml in both
groups of allergic patients. Inhibition of IgE production
after anti-CD40þ interleukin-4 stimulation in the
presence of resiquimod (10 ng per ml) was comparable
between all the groups. In normal donors median
inhibition of IgE synthesis was 93%, in seasonal allergic
rhinitis patients 77%, and in patients with atopic der-
matitis 72%. In order to rule out antiproliferative e¡ects
of resiquimod, which might in£uence IgE production,
we also studied proliferation of peripheral blood mono-
nuclear cells from normal donors, which remained un-
changed in the presence of resiquimod at 0.1^10 ng per
ml but was inhibited at 100 or 1000 ng per ml. In search
of possible mechanisms responsible for the observed
inhibition of IgE production, we analyzed the expres-
sion and production of molecules that are known to
modulate IgE production, namely CD23 and inter-
feron-c. CD23 expression on B cells was lower in the
presence of resiquimod (10 ng per ml) in anti-
CD40þ interleukin-4 stimulated cells, whereas interfer-
on-c was strongly induced (4^6-fold) by resiquimod
(10 ng per ml). Furthermore, by using neutralizing
interferon-c monoclonal antibodies, we show that inhi-
bition of IgE production occurred in an interferon-c-
dependent manner.Taken together our results show that
resiquimod is a potent modulator of IgE production
in vitro in normal but also in allergic donors. Key words:
allergy/atopic dermatitis/CD40/interleukin 4/resiquimod. J Invest
Dermatol 119:1059 ^1064, 2002
I
miquimod and resiquimod belong to the family of imida-
zoquinolines, which are known to have antiviral and anti-
tumor properties. Initially imiquimod was discovered to
protect guinea pigs from herpes simplex virus infection
(Miller et al, 1985; Harrison et al, 1988). Further studies re-
vealed antiviral activities in other animal models including cyto-
megalovirus infection of guinea pig (Chen et al, 1988) or
arbovirus infection in mice (Kende et al, 1988). Furthermore the
treatment with imiquimod has also been shown to inhibit tumor
growth in a number of murine models including MC-26 colon
carcinoma, RIF-1 sarcoma, and Lewis lung carcinoma in mice
(Sidky et al, 1992); even curative e¡ects have been demonstrated
on the growth of mouse bladder carcinoma FCB (Sidky et al,
1990). It was shown, however, that the imidazoquinolines have
no direct antiviral and antitumor properties on cells but are in-
stead potent inducers of cytokines and enhancers of cell-mediated
immune responses. First, interferon-g (IFNa) has been proven to
be an important mediator of antitumor activity by using antibo-
dies against IFNa (Sidky et al, 1992). The imidazoquinolines have
also been demonstrated to induce detectable amounts of other cy-
tokines such as IFNa and IFNg, interleukin-6 (IL-6), and tumor
necrosis factor a (TNFa) in vivo and in vitro (Reiter et al, 1994;
Testerman et al, 1995;Wagner et al, 1998).
It has been shown from phase I clinical trials with administra-
tion of oral imiquimod to patients with refractory cancer and pa-
tients with asymptomatic HIV infection that a rise of the serum
IFN, neopterin, and b2-M occurs during treatment, but with
variable e¡ects on tumor growth and virus load and with partly
serious side-e¡ects (Savage et al, 1996; Goldstein et al, 1998). Re-
cent clinical studies demonstrated e⁄cacy of topical imiquimod
in the treatment of human external genital warts (Beutner et al,
1998a; 1998b; Maitland and Maw, 2000), and imiquimod cream
(5%) became available for the treatment of external genital warts
caused by human papilloma virus infections. In recent studies it
was shown that resiquimod and imiquimod modulate the TH1/
TH2 response by inducing the production of TH1 cytokines like
IFNg and the production of IL-12, which directs the di¡erentia-
tion of naive activated CD4Tcells intoTH1 e¡ector cells, and by
inhibiting the TH2 cytokines IL-4 and IL-5 in mouse and
human culture systems (Wagner et al, 1998). These data suggest
that imiquimod and resiquimod may have therapeutic applications
in atopic diseases that are associated with an overexpression of
TH2 cytokines. In vivo studies have demonstrated inhibition of
Ag-induced IgE synthesis by both imiquimod and resiquimod
(Vasilakos et al, 2000). As TH2 cytokines are important inducers
of IgE-isotype switching and IgE is the key molecule in the
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pathogenesis of allergic diseases, we studied the e¡ects of
resiquimod on IgE production by unstimulated and anti-CD40þ
IL-4 activated peripheral blood mononuclear cells (PBMC)
from healthy donors (HD), patients su¡ering from atopic
dermatitis (AD), and patients su¡ering from seasonal allergic
rhinoconjunctivitis (AR). In search of possible mechanisms
responsible for the observed inhibition of IgE, we analyzed
also the e¡ects of resiquimod on the expression of the low a⁄nity
IgE receptor CD23 on peripheral B cells and the production of
the cytokines IL-12 and IFNg on PBMC, which are known to
modulate IgE production.
MATERIALS AND METHODS
Patients Heparinized blood samples were obtained from adult healthy,
nonallergic donors (HD) (n¼ 6) and patients from the Department
of Dermatology and Allergy of the ChariteŁ Berlin, Germany, su¡ering
from atopic dermatitis (AD) (n¼ 6) or su¡ering from seasonal allergic
rhinoconjunctivitis (AR) (n¼ 6). All AR patients were sensitized against
grass pollen proven by clinical history, positive skin prick test, and the
presence of speci¢c IgE levels against grass pollen. The AD patients were
polysensitized individuals. All of them were sensitized to pollen, house
dust mite, and cat dander proven by skin prick test and speci¢c IgE levels
ranging from40.35^100 kU per ml.
The blood drawings from allergic and nonallergic donors for in vitro
investigations were approved by a local ethics committee.
We determined the total serum IgE levels in the di¡erent analyzed
groups. The lowest total serum IgE levels were found in HD (n¼ 6) and
ranged from 3.4 ng per ml to 49.3 ng per ml (median value, 19.7 ng per ml).
AR patients (n¼ 6) presented higher total serum IgE levels ranging from
7.3 ng per ml to 664.6 ng per ml (median value, 115.6 ng per ml). The
highest total serum IgE levels were found in AD patients (n¼ 6) and
ranged from 563.9 ng per ml to 2525 ng per ml (median value, 2000 ng
per ml).
Cell preparation The PBMC were separated from heparinized whole
blood by Ficoll density gradient centrifugation (Biochrom, Germany) and
washed repeatedly in phosphate-bu¡ered saline (PBS) before being used
for further investigations. Cell cultures were performed in £at-bottomed
24- or 96-well plates in RPMI 1640 medium supplemented with 10%
fetal bovine serum, glutamine (2mM), penicillin (100U per ml), and
streptomycin (100mg per ml). The cells were incubated at 371C in a water-
saturated atmosphere containing 5% CO2.
10 Microliter of WST-1 Enzymatic proliferation assay WST-1 was
obtained from Boehringer Mannheim, Germany. 105 cells per well were
cultured for 4 d and then 10ml of WST-1 reagent were added; after being
incubated for three more hours the reaction was photometrically measured
at 450 nm with aTitertec ELISA-Reader.
To determine the cell viability PBMC samples were stained using
trypan blue exclusion after incubation and counted.
Flow cytometry Flow cytometry was performed with PBMC that had
been cultured for 48 h at a concentration of 2106 cells per ml. After
several washings with PBS, 1106 cells were resuspended in 100 ml
staining bu¡er [2% bovine serum albumin (BSA) in PBS; pH 7.4; 0.1%
sodium azide], double-stained with 10 ml anti-CD19 £uorescein isothio-
cyanate (FITC) conjugated antibody (Biosource, Ratingen, Germany) and
with 10ml of phycoerythrin (PE) conjugated anti-CD23 antibody (Biosource),
and incubated on ice for 30min. The cells were then washed and ¢xed
in PBS with 2% paraformaldehyde. The isotypes IgG1-FITC and IgG1-PE
(from Immunotech, Krefeld, Germany) were used as negative controls.The
measurements were carried out using a Coulter XL £ow cytometer and
evaluated using Coulter System 2 software. The percentage of double-
positive B cells and the mean £uorescence intensity (MFI, measure of the
density of receptors per cell) of the PE-conjugated antibody were
determined.
Ig enzyme-linked immunosorbent assay (ELISA) IgE-ELISA was
performed with supernatants from 106 cells per ml that had been cultured
for 10 d. The monoclonal antibodies for IgE detection (clones HP 6061 and
HP 6029) were kindly provided by Robert Hamilton, Asthma and Allergy
Center, Johns Hopkins University, Baltimore, MD. For the Ig assays,
immuno plates (Nunc, Wiesbaden, Germany) were coated overnight at
41C with antihuman IgE-Fc monoclonal antibody (HP 6061, 2 mg per ml)
diluted in 0.1 M bicarbonate bu¡er. On the next morning the wells
were blocked for 1h with 2% BSATris bu¡er. After several washings,
supernatants and internal standards were incubated in duplicate for 3 h
at room temperature. Thereafter, the second antihuman IgE detection
monoclonal antibody (HP 6029, 1 mg per ml) was added and incubated for
another 2 h. The second anti-IgE monoclonal antibody was biotinylated
and wells were incubated after washing for another hour with alkaline
phosphatase conjugated streptavidin. Following the ¢nal reaction with
phosphatase substrate (Sigma, Dreieich, Germany), plates were read in
a microplate ELISA reader at 405 nm, and the amount of IgE was
calculated according to the standard curve. The variations of readings in
duplicate cultures never exceeded 15%. The sensitivity of the ELISA
ranges from 0.5 to 25 ng per ml.
IFNc and IL-12 p40 ELISA IFNg and IL-12 p40 were determined in
supernatants of 2106 PBMC per ml cultured for 48 h according to the
manufacturer’s instruction (R&D Systems, Minneapolis, MN).
Statistical analysis Wilcoxon’s signed rank test for matched pairs
was performed to compare the results within the same group. The
Mann^Whitney U test was used to determine di¡erences between the
di¡erent groups studied. Statistically signi¢cant di¡erences were considered
to be p-values o 0.05.
RESULTS
Inhibition of baseline IgE production by resiquimod in AR
and AD patients In order to study the role of resiquimod on
total IgE production of unstimulated and anti-CD40þ IL-4
stimulated PBMC from HD, AD, and AR patients, cells were
incubated with di¡erent concentrations of resiquimod (0.1ng per
ml, 1ng per ml, 10 ng per ml). In unactivated PBMC from HD no
basal IgE production was observed. By contrast, spontaneous IgE
production occurred in unactivated PBMC from AR patients
(median values, 1.73 ng per ml 7 0.6 or 9.8% of anti-CD40
þ IL-4 stimulation) and from AD patients (median values,
3.2 ng per ml 7 2.3 or 32% of anti-CD40þ IL-4 stimulation).
This baseline IgE production from unstimulated PBMC by AR
and AD patients was inhibited by resiquimod. In AR patients all
concentrations of resiquimod (0.1^10 ng per ml) inhibited IgE
production, whereas in AD patients only a concentration of
10 ng per ml resiquimod inhibited IgE synthesis (Fig 1ac).
Inhibition of IgE production of anti-CD40+IL-4 stimulated
cells by resiquimod Stimulation of B cells with anti-
CD40þ IL-4 is known to induce IgE production. To study the
role of resiquimod in the induction of IgE synthesis, PBMC
were stimulated with anti-CD40þ IL-4 with and without
resiquimod. Our data show a strong and signi¢cant induction of
IgE production after the stimulation of PBMC with anti-
CD40þ IL-4 in all three study groups, with the lowest
induction of IgE in HD and the highest IgE induction in AR
patients (median values: HD, 5.7 ng per ml 7 1.7; AR, 17.4 ng
per ml 7 12.8; AD, 10 ng per ml 7 5.9). Furthermore, we
observed that IgE synthesis was strongly inhibited in anti-
CD40þ IL-4 activated PBMC by resiquimod, starting at 0.1ng
per ml and with the strongest inhibition of IgE production by
10 ng per ml resiquimod in all study groups. In comparison to
anti-CD40þ IL-4 activated cells without resiquimod, statistical
signi¢cance was reached at a concentration of 10 ng per ml
resiquimod in all three analyzed groups. In HD median IgE
synthesis was inhibited to 7% of anti-CD40þ IL-4 stimulation
or 0.4 ng per ml 7 0.9, whereas in AR patients IgE production
was inhibited to 23% of anti-CD40þ IL-4 stimulation or 4 ng
per ml 7 2.2, and in AD patients to 28% of anti-CD40þ IL-4
stimulation or 2.8 ng per mI7 4.4 (Fig 1a^c).
Resiquimod inhibits proliferation of PBMC In order to
rule out antiproliferative e¡ects of resiquimod, which might
be responsible for the observed inhibition of IgE production,
we also studied proliferation of PBMC in the presence of
resiquimod. Our data show that resiquimod did not a¡ect
baseline proliferation of unstimulated PBMC through concen-
trations up to 100 ng per ml. We did observe antiproliferative
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e¡ects of resiquimod in unstimulated PBMC at a concentration
of 1000 ng per ml, however, without reaching statistical
signi¢cance (data not shown). Furthermore, a signi¢cant increase
of PBMC proliferation was observed in anti-CD40þ IL-4
stimulated cells (average 45% 7 5.5). In these cells resiquimod
did not a¡ect the proliferation up to a concentration of 10 ng
per ml. In contrast to unstimulated PBMC, resiquimod showed
signi¢cant antiproliferative e¡ects in anti-CD40þ IL-4 stimulated
PBMC starting at a concentration of 100 ng per ml (Fig 2).
Trypan blue exclusion showed that the cell viability of the
PBMC was not decreased in the presence of resiquimod at
concentrations of resiquimod up to 10 ng per ml.
Resiquimod downregulates CD23 expression on peripheral
B cells In search of possible mechanisms responsible for the
observed inhibition of IgE synthesis, we analyzed next the
expression of the low a⁄nity IgE receptor CD23 on peripheral
B cells, which is known for its pathophysiologic importance in
type I hypersensitivity reactions and its capability to modulate
IgE production (Bonnefoy et al, 1997). As shown in Fig 3(a), (b),
baseline expression and density of CD23 on peripheral B cells
before culture (day 0) were not markedly di¡erent in the groups
of HD and AR donors (% CD23þB cells, 35.5%77.1 and
40.5%710; MFI, 0.770.11 and 0.870.23, respectively), whereas
baseline expression and density of CD23 on peripheral B cells
from AD patients were signi¢cant higher (% CD23þ B cells,
57%78.2; MFI, 1.5570.35). The percentage of CD23þB cells
and the MFI decreased after culture for 48 h in unactivated B
cells in all three study groups. Addition of resiquimod (10 ng per
ml) to unactivated cells resulted in a slight upregulation of CD23
in percentage and density for HD and AR patients, whereas there
was no marked in£uence on B cells of AD patients (Fig 3a, b).
Stimulation of PBMC with anti-CD40þ IL-4 for 48 h resulted
in a strong, signi¢cant increase of the percentage of CD23þ B
cells (53.8%73.3, 57.6%76.8, and 74.4%72.5, respectively) and
the MFI (1.5270.4, 1.6872.2, and 6.0771.8, respectively) in
comparison with unstimulated cells (Fig 3a, b) from HD, AR,
and AD donors. The strongest increase of the expression of
CD23 on peripheral B cells as well as receptor density occurred
in AD patients; this was found to be signi¢cantly higher in
comparison to the expression and MFI of CD23 on B cells of
HD. B cells from anti-CD40þ IL-4 activated cells in the
presence of resiquimod (10 ng per ml) in comparison to activated
cells without this agent showed less expression of the CD23
receptor on their surface, and when compared to cells that were
only treated with anti-CD40þ IL-4 the receptor density was less
intense. In HD 19.8%74.3 of the B cells expressed the CD23
receptor on their surface, whereas in AR patients it was 5%75
and in AD patients 8.9%76 B cells compared with activated cells
without resiquimod (10 ng per ml). In proportion, the percentage
as well as the density of CD23 on B cells of AR patients was not
reduced as much by resiquimod and our data show that the
strongest inhibition of the expression of CD23 by resiquimod
was achieved on B cells of HD (% reduction of MFI in HD,
60.5%728.6; in AR, 37.5%725.5; in AD, 50.9%733.6) (Fig 3a,
b). Although a clear tendency is present, statistical signi¢cance of
CD23 downregulation by resiquimod was not reached. The
analysis of CD19 expression itself revealed a stable expression in
the presence of resiquimod.
Upregulation of IFNc and IL-12 production in the presence
of resiquimod IFNg and IL-12 are known to modulate the
immune response strongly by favoring a TH1 response and in
inhibiting TH2 cell responses. To ¢nd out whether the synthesis
Figure1. Resiquimod inhibits IgE production in vitro. Inhibition of
IgE production was observed in anti-CD40+IL-4 stimulated PBMC from
HD (a), and from unactivated and anti-CD40+IL-4 stimulated human
PBMC (106 cells per ml) in AR patients (b) and AD patients (c). PBMC
were incubated 10 d alone, in the presence of resiquimod (0.1^10 ng per
ml), or in the presence of anti-CD40 (1 mg per ml)+IL-4 (5 ng per ml)
alone and in combination with resiquimod (0.1^10 ng per ml). IgE levels
were detected in the supernatants by ELISA. All experiments were done in
duplicate. Data are expressed as median values 7 SEM of percentage anti-
CD40+IL-4 stimulation. ust, unstimulated; st, anti-CD40+IL-4 stimu-
lated. n¼ 6. npo 0.05.
Figure 2. Resiquimod inhibits CD40+IL-4 mediated proliferation
of PBMC in vitro in concentrations>10 ng per ml. Anti-CD40 (1 mg
per ml)+IL-4 (5 ng per ml) mediated proliferation of human PBMC from
HD was studied with or without resiquimod at concentrations from 0.1 ng
per ml to 1000 ng per ml. PBMC (106 cells per ml) were incubated for 4 d,
and 10 ml of WST-1 reagent was added for the last 3 h of incubation. The
reaction was measured photometrically at 450 nm.All experiments were
done in triplicate and the data are expressed as median values 7 SEM
of percentage anti-CD40+IL-4 stimulation. ust, unstimulated; st, anti-
CD40+IL-4 stimulated. n¼ 6. npo 0.05.
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of IFNg and IL-12 is increased by PBMC in the presence of
resiquimod, we analyzed their production in unstimulated and
in anti-CD40þ IL-4 activated PBMC in comparison to
unstimulated and anti-CD40þ IL-4 activated PBMC in the
presence of resiquimod (10 ng per ml) after an incubation of
48 h. In all three studied groups resiquimod (10 ng per ml)
induced a strong increase in the synthesis of IFNg in unactivated
but also in anti-CD40þ IL-4 activated PBMC. In anti-
CD40þ IL-4 activated PBMC, however, IFNg production was
increased by resiquimod even more than in unactivated cells
(4^12-fold and 2^5-fold, respectively) (Table I). As expected,
IFNg productionwas not enhanced in the presence of anti-CD40þ
IL-4 compared to unactivated cells.We noticed the same e¡ects
on the production of IL-12 in anti-CD40þ IL-4 activated
PBMC in response to resiquimod (10 ng per ml), although the
increase of IL-12 was much less pronounced (o 2-fold) In
contrast to IFNg, IL-12 was not markedly induced by
resiquimod (10 ng per ml) in unstimulated PBMC, whereas it
was only induced in the presence of anti-CD40þ IL-4 in
comparison to unstimulated PBMC (Table II).
Inhibition of IgE production by resiquimod is IFNc
dependent We showed above that resiquimod strongly induced
IFNg production in unstimulated and anti-CD40þ IL-4 activated
PBMC. To elucidate whether IFNg is responsible for the observed
inhibition of IgE synthesis by resiquimod we added neutralizing
IFNg monoclonal antibodies (10 mg per ml) to CD40þ IL-4
stimulated PBMC in the presence of resiquimod. Our results
show that the strong inhibition of IgE production in anti-
CD40þ IL-4 activated PBMC by resiquimod in HD (median
value 19% of anti-CD40þ IL-4 stimulation) was partially
inhibited by the addition of neutralizing IFNg monoclonal
antibodies (median value 62% of anti-CD40þ IL-4 stimulation).
In the presence of IFNg monoclonal antibodies to anti-
CD40þ IL-4 activated PBMC IgE synthesis, as expected, was
found to be slightly increased (median value 111% of anti-
CD40þ IL-4 stimulation) (Fig 4). IgG1 monoclonal antibodies
were used as isotype controls to exclude nonspeci¢c e¡ects of
IFNg monoclonal antibodies on IgE synthesis.
DISCUSSION
In this paper we demonstrate that the imidazoquinoline resiqui-
mod inhibits anti-CD40þ IL-4 mediated IgE production by
PBMC from normal and allergic donors. Furthermore, we show
inhibition of spontaneous baseline IgE production by PBMC
from AR and AD donors by resiquimod. This inhibition of IgE
production by resiquimod is T cell dependent and occurs in an
IFNg dependent manner, because neutralizing IFNg monoclonal
antibodies partly abolish the e¡ects of resiquimod on IgE produc-
tion. Similar results have been observed in mice immunized with
antigen and resiquimod (Vasilakos et al, 2000). Finally, our data
show that resiquimod leads to a downregulation of CD23 ex-
pression on peripheral B cells, which also occurs in an IFNg de-
pendent manner (data not shown). Allergic diseases like
rhinoconjunctivitis and atopic dermatitis are characterized by a
TH2-dominated immune response. IgE also plays an important
pathophysiologic role for the exacerbation of these atopic dis-
eases, however. This has been underlined by recent studies apply-
ing chimeric anti-IgE monoclonal antibody in the treatment for
IgE-mediated diseases (Adelroth et al, 2000). Speci¢c immu-
notherapy (SIT) has been proven by theWHO as a causal thera-
peutic approach for allergic diseases. It leads towards a TH1 shift,
as several studies regarding the immunologic mechanisms of SIT
have shown previously (Bellinghausen et al, 1997; Akdis and Blas-
er, 1999). These e¡ects of SIT include an induction of IFNg pro-
duction as well as downregulation of CD23 expression. SIT is
time consuming and expensive. Therefore, the search for new
molecules that are capable of directing the immune system to-
wards a TH1 response began many years ago. These include, for
example, the application of IL-4 R antagonists and more recently
CpG oligonucleotides for the treatment of allergic diseases
(Carballido et al, 1995; Metzger and Nyce, 1999). CpG molecules
bind toTLR-9 and it has been demonstrated that resiquimod ex-
erts its e¡ects through binding of TLR-7, indicating that binding
of these receptors plays an important role triggering aTH1-direc-
ted response (Hemmi et al, 2000; 2002). This is only observed,
however, when the B cell response is studied within the other
cells of the periphery; if only B cells are cultured, B cell activat-
ing e¡ects were observed instead (Bishop et al, 2001).
In recent studies it has been shown that resiquimod modulates
the TH response by inducing the production of TH1 cytokines
IFNg and IL-12 and by inhibiting the TH2 cytokines IL-4 and
IL-5 in mouse and human culture systems (Wagner et al, 1998),
suggesting that resiquimod may have therapeutic properties not
only for the treatment of herpes virus infection (Bernstein et al,
2001; Miller et al, 2002) but also in atopic diseases. Indeed, we
could show in this study that resiquimod dose dependently inhi-
bits IgE production in anti-CD40þ IL-4 stimulated PBMC.This
was observed not only in nonallergic donors but, as has been re-
ported previously, also in allergic donors such as patients su¡ering
Figure 3. Comparison of the percentage (a) and the MFI (b) of CD23 ex-
pression on peripheral B cells with HD, AR, and AD patients. Median
values 7 SEM of baseline expression (day 0) and expression of B cells
after incubation (48 h) of anti-CD40+IL-4 (1 mg per ml and 5 ng per ml)
stimulated PBMC alone and in combination with resiquimod (10 ng per
ml) are shown from six experiments. Cells were double-stained (anti-
CD19-FITC and anti-CD23-PE) and analysis was carried out using a
Coulter XL £ow cytometer. The percentage of double-positive B cells
was calculated from immuno£uorescence cytograms. ust, unstimulated; st,
anti-CD40+IL-4 stimulated. Signi¢cances are indicated for each group re-
lated to day 0. npo 0.05.
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from allergic rhinitis or atopic dermatitis. Resiquimod inhibits
IgE production also in vivo as has been shown previously in mice
(Tomai et al, 2000; Vasilakos et al, 2000). In this study decreased
total IgE levels and increased OVA-speci¢c IgG2a levels after
OVA sensitization were detected when resiquimod was used as a
vaccine adjuvant. These results suggested an IFNg dependent
e¡ect in vivo as well, as IgG2a production is IFNg dependent.
The same in vivo results were observed in another study that ana-
lyzed the adjuvant activities of resiquimod in mice (Vasilakos et al,
2000). In this study, however, IgE inhibition by resiquimod was
also present in IFNg-de¢cient mice, and these authors suggested
an important role of IFNa andTNFa in their in vivomouse mod-
el. In our study we observed the induction of IFNg by resiqui-
mod and we could furthermore demonstrate that inhibition of
IgE production by resiquimod is partly IFNg dependent.
Whether IFNa and TNFa may also be involved in the inhibition
of IgE production by resiquimod in vitro in the human system is
currently under investigation. The potential antiallergic proper-
ties of IFNg have been implicated by numerous studies. These
include the observation that IFNg, which is mainly produced by
TH1 cells, favors aTH1 response by inhibitingTH2 cell prolifera-
tion (Gajewski and Fitch, 1988). The e¡ects of IFNg on isotype
switching include the induction of IgG3 and IgG2a, but inhibi-
tion of IgG1 and IgE, production (Co¡man et al, 1993). The inhi-
bition of IgE production occurs through downmodulation of
epsilon-germline transcription (Xu and Rothman, 1994); how-
ever, the exact mechanisms have not been described so far. These
observations have led to several clinical trials in diseases with in-
creased IgE levels including atopic dermatitis. Although INFg
therapy resulted in inhibition of spontaneous IgE production
in vitro, only negligible e¡ects were observed on serum IgE levels
(Hani¢n et al, 1993; Reinhold et al, 1993), and as the clinical re-
sponse rates were also not convincing these approaches did not
warrent future studies. Therefore, such a therapeutic strategy
would need to be combined with, for example, a therapy neutra-
lizing pre-existing IgE. As the latest development of humanized
anti-IgE monoclonal antibodies includes such e¡ects (Corne et al,
1997), this may be useful for new therapeutic strategies. CD23,
the low a⁄nity IgE receptor, is expressed on several cells includ-
ing B lymphocytes and monocytes. In this study we could show
that CD23 expression is enhanced on B cells from AD donors, as
has been described previously. The expression of CD23 has been
shown to be regulated by cytokines. CD23 expression is induced
by IL-4 and inhibited by IFNg (Te Velde et al, 1990). Our obser-
vations that CD23 expression is downmodulated in the presence
of resiquimod and that neutralizing anti-IFNg abolishes these
e¡ects (unpublished observations) indicate that the decreased
expression of CD23 in the presence of resiquimod is IFNg
dependent. As interaction between CD23 and CD21 plays a role
in IgE regulation, with CD23CD21 binding leading to an
increase in IL-4 induced IgE production (Aubry et al, 1992), and
as sCD23 enhances IL-4 induced IgE synthesis (Bonnefoy et al,
1997; Wheeler et al, 1998), a decreased CD23 expression and
decreased sCD23 production may contribute to the inhibition
of IgE production by resiquimod.
Table I. E¡ects of resiquimod (10 ng per ml) on the IFNg production of unactivated and anti-CD40 (1 mg per ml)þ IL-4
(5 ng per ml) stimulated PBMC in HD, AR, and AD patients
healthy donors AD patients AR patients
Exp.1 Exp.2 Exp.3 Exp.1 Exp.2 Exp.3 Exp.1 Exp.2 Exp.3
ust 9 17 o3 4 4 o3 9 o3 3
ustþ resiquimod 10 ng/ml n.d. 90 25 12 24 6 18 6 14
anti-CD40/IL-4 6 20 o3 o3 5 3 10 o3 5
anti-CD40/IL-4þ resiquimod 10 ng/ml 73 102 36 25 57 12 43 20 42
PBMC (2106 cells per ml) were incubated for 48 h and then IFNg (pg per ml) was measured in the supermantants by ELISA, n¼ 3 of each group are shown, ust,
unstimulated.
Table II. E¡ects of resiquimod (10 ng per ml) on the IL-12 p40 production of unactivated and anti-CD40 þ IL-4 (1 mg per ml
and 5 ng per ml) stimulated PBMC in HD, AR, and AD patients
healthy donors AD patients AR patients
Exp.1 Exp.2 Exp.3 Exp.1 Exp.2 Exp.3 Exp.1 Exp.2 Exp.3
ust 29 o15 o15 o15 o15 o15 o15 o15 o15
ustþ resiquimod 10 ng/ml 40 o15 o15 o15 18 21 n.d. o15 o15
anti-CD40/IL-4 54 20 15 29 36 167 23 o15 63
anti-CD40/IL-4þ resiquimod 10 ng/ml 45 26 21 39 59 153 31 26 77
PBMC (2106) were incubated 48 h and IL-12 p40 (pg per ml) was measured in the supernatants by ELISA. n¼ 3 of each group are shown. ust, unstimulated.
Figure 4. Neutralizing IFNc-monoclonal antibodies abolish resi-
quimod-mediated inhibition of IgE synthesis in anti-CD40 (1 lg per
ml)+IL-4 (5 ng per ml) stimulated PBMC in HD. PBMC (1  106
cells per ml) were incubated 10 d alone and in the presence of anti-CD40
(1 mg per ml) and IL-4 (5 ng per ml) alone or in combination with resiqui-
mod (10 ng per ml) and/or neutralizingmonoclonal antibodies against IFNg
(10 mg per ml). IgG1 served as a control monoclonal antibody and was used
at the same concentration. IgE levels were detected in the supernatants by
ELISA. All experiments were done in duplicate. Data are expressed as med-
ian values 7 SEM of percentage anti-CD40+IL-4 stimulation. ust, unsti-
mulated; st, anti-CD40+IL-4 stimulated. n¼ 6. npo 0.05.
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Taken together, we could show in this study that the immune
modulator resiquimod is a potent inhibitor of IgE production
in vitro. This inhibition of IgE production occurs not only in
anti-CD40þ IL-4 stimulated cells, but also in PBMC from aller-
gic donors su¡ering from rhinitis or atopic eczema. These ¢nd-
ings along with previous ¢ndings (Vasilakos et al, 2000) support
the potential use of this class of immune modi¢ers in allergic dis-
eases. Resiquimod and other immune response modulators are
currently under investigation regarding their antiallergic e¡ects
in appropiate in vivo models.
This work was supported by B. Benninghof from 3M Pharmaceuticals. The ¢nal
authorization for publication by 3M Pharmaceuticals was given on July 29, 2002.
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